Riskpilot← Back to searchSign inGet full accessJohn Ouchterlony AB
ABActiveOrg 5567369110Economic activity was not specified by tax authority · NACE 0000Est. 20070 employees
Revenue 2024
SEK 0
EBITDA margin
—
0% vs 2023
Equity ratio
3.6%
Financial strength
Net profit 2024
SEK -13K
0% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -13K | +0% |
| Net profit | SEK -13K | +0% |
| Total assets | SEK 2,8M | +0% |
| Equity | SEK 101K | -11% |
| Employees | 0 | — |
Legal name
John Ouchterlony AB
Org number
5567369110
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
3 september 2007
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva vetenskaplig konsultverksamhet, medicinsk-tekniskt utvecklingsarbete, läkartjänster, handel med läkemedel, hälsoprodukter, värdepapper och fast egendom samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −10 | −10 | −11 | −13 | −13 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −10 | −10 | −11 | −13 | −13 |
| Net financials | — | — | — | — | — |
| Profit before tax | −10 | −10 | −11 | −13 | −13 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −10 | −10 | −11 | −13 | −13 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 851 | 2 841 | 2 831 | 2 818 | 2 804 |
| Equity | 518 | 325 | 127 | 114 | 101 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 333 | 2 516 | 2 703 | 2 703 | 2 703 |
| Total debt | 2 333 | 2 516 | 2 703 | 2 703 | 2 703 |
EBITDA margin
-1300000.0%
This company
15.8%
Market median
-8227948% vs market
20202024
Equity ratio
3.6%
This company
38.2%
Market median
-91% vs market
20202024
Return on equity
-12.9%
This company
18.4%
Market median
-170% vs market
20202024
Net profit margin
-1300000.0%
This company
8.1%
Market median
-16049483% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
26.76×
This company
0.62×
Market median
-4216% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RM | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
John Ouchterlony AB 
Aktiebolaget ImmunoBoard members of John Ouchterlony AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rolf Martin von Brömsen | Audit | 0 companies |
| John Rolf Örjan Ouchterlony | Board of Directors | 0 companies |
| Frank Bertel Ouchterlony | Deputy Board Member | 0 companies |